Orphan Drug Designation(ODD)
A status granted to drugs intended to treat rare diseases affecting fewer than 200,000 people in the US.
Usage Examples
- The enzyme replacement therapy received Orphan Drug Designation.
- Orphan exclusivity prevents generic approval for 7 years.
- FDA granted orphan designation for the rare pediatric indication.
What is ODD?
Orphan Drug Designation (ODD) is granted by FDA to drugs intended to treat, diagnose, or prevent rare diseases or conditions affecting fewer than 200,000 people in the US (or where there's no reasonable expectation of recovering development costs).
Benefits include 7 years of market exclusivity upon approval, tax credits for qualified clinical trials, waiver of PDUFA application fees, and FDA assistance in protocol design. The Orphan Drug Act (1983) created these incentives.
Orphan designation is distinct from approval. Products must still demonstrate safety and effectiveness. Multiple products may receive orphan designation for the same condition.
Regulatory Context
This term appears most often in submission & approval workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside ORPHAN DRUG ACT, 21 CFR 316.
When This Matters
- The enzyme replacement therapy received Orphan Drug Designation.
- Orphan exclusivity prevents generic approval for 7 years.
- FDA granted orphan designation for the rare pediatric indication.
Common Mistakes
- Treating submission readiness as a formatting-only check without lifecycle validation.
- Using outdated guidance references across modules and summaries.
- Missing cross-functional review between RA, CMC, and quality before submission.
Related Regulations
Frequently Asked Questions
In the US, a rare disease affects fewer than 200,000 people. In the EU, it's defined as affecting fewer than 5 in 10,000 people.
Yes, if developed for a rare indication. The same drug molecule can have orphan status for one indication and non-orphan status for another.
Related Terms
Related Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
Track ICH quality guidelines automatically and get alerts when changes impact your products
Related Regulatory Intelligence
Related Actions
Sources & References
